New positive phase 1/2 interim data presented at worldsymposium™ shows neurocognitive development of young mps iiia patients preserved up to three years following treatment with abeona's abo-102 gene therapy

In addition to preservation of neurocognitive development with abo-102 in mps iiia, new clinical results of abo-102 in mps iiia and abo-101 in mps iiib continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects
ABEO Ratings Summary
ABEO Quant Ranking